Registration Strip Icon for discussion 登録して、同じ考えを持つ投資家と議論するためのアクティブなフォーラムで相互作用するためのアクティブなフォーラムに参加してください。

PFE

Pfizer (PFE)

Pfizer Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NYSE:PFE
日付受信時刻ニュースソース見出しコード企業名
2024/05/1321 : 00PR Newswire (US)Astellas Showcases Scientific Advancements Across its Oncology Portfolio at 2024 ASCO Annual MeetingNYSE:PFEPfizer Inc
2024/05/1320 : 16IH Market NewsArm Sets 2025 Target for AI Chip Development, Amazon and Microsoft Commit Billions to French Investments, and MoreNYSE:PFEPfizer Inc
2024/05/0922 : 01Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNYSE:PFEPfizer Inc
2024/05/0920 : 53IH Market NewsBain Capital in Talks to Acquire PowerSchool; Blackstone Emerges Victorious in Hipgnosis Bidding War, and More NewsNYSE:PFEPfizer Inc
2024/05/0904 : 56Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NYSE:PFEPfizer Inc
2024/05/0619 : 45Business WirePfizer Announces New Chief Strategy and Innovation OfficerNYSE:PFEPfizer Inc
2024/05/0122 : 12IH Market NewsCVS Health, Starbucks, Shares Weaker; Pinterest SoarsNYSE:PFEPfizer Inc
2024/05/0119 : 45Business WirePfizer Reports First-Quarter 2024 ResultsNYSE:PFEPfizer Inc
2024/04/3007 : 40Business WireFDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerNYSE:PFEPfizer Inc
2024/04/3007 : 40Business WireTIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerNYSE:PFEPfizer Inc
2024/04/2919 : 45Business WirePfizer Highlights Progress in Accelerating Breakthrough Cancer Medicines at ASCO 2024 Annual MeetingNYSE:PFEPfizer Inc
2024/04/2620 : 48IH Market NewsAnglo American Rejects BHP Group’s Offer, Toyota Invests $1.4 Billion in Indiana, and More NewsNYSE:PFEPfizer Inc
2024/04/2619 : 45Business WireU.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia BNYSE:PFEPfizer Inc
2024/04/2505 : 37Business WirePfizer Declares Second-Quarter 2024 DividendNYSE:PFEPfizer Inc
2024/04/2420 : 28IH Market NewsCoca-Cola and Microsoft Sign Billion-Dollar Agreement, Apple Event Set for May 7, and More NewsNYSE:PFEPfizer Inc
2024/04/2221 : 08Business WireEuropean Commission Approves Pfizer’s EMBLAVEO® for Patients with Multidrug-Resistant Infections and Limited Treatment OptionsNYSE:PFEPfizer Inc
2024/04/1123 : 00Business WirePfizer Invites Shareholders to Attend Virtual-Only 2024 Annual Meeting of Shareholders on April 25NYSE:PFEPfizer Inc
2024/04/1020 : 13IH Market NewsDelta Generates US$37 Million Profit in Q1, Google and Intel Unveil Cutting-Edge AI Chips, and More NewsNYSE:PFEPfizer Inc
2024/04/0919 : 45Business WirePfizer Announces Positive Top-Line Results from Phase 3 Study of ABRYSVO® in Adults Aged 18 to 59 at Increased Risk for RSV DiseaseNYSE:PFEPfizer Inc
2024/04/0901 : 44PR Newswire (US)ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering ManagerNYSE:PFEPfizer Inc
2024/03/2620 : 20IH Market NewsSuper Micro Computer and Seagate Shares Surge on Analyst Optimism in Pre-Market Trading, and Latest NewsNYSE:PFEPfizer Inc
2024/03/2120 : 17IH Market NewsApple Pre-Market Drop Due to Antitrust Threats, Surprising Profit Boosts Micron Shares, and Latest Market UpdatesNYSE:PFEPfizer Inc
2024/03/2023 : 00Business WirePfizer Invites Public to View and Listen to Webcast of May 1 Conference Call with AnalystsNYSE:PFEPfizer Inc
2024/03/1920 : 33IH Market NewsUnilever Initiates Ice Cream Division Spin-Off and Announces Job Cuts; Berkshire Ramps Up Share Buyback Efforts, and MoreNYSE:PFEPfizer Inc
2024/03/1820 : 10IH Market NewsApple & Google in Talks for Gemini AI on iPhone, Nvidia’s GTC Conference Today, and Latest NewsNYSE:PFEPfizer Inc
2024/03/1317 : 00Business WireEuropean Commission Approves Pfizer’s PREVENAR 20® to Help Protect Infants and Children Against Pneumococcal DiseaseNYSE:PFEPfizer Inc
2024/03/1219 : 45Business WirePfizer Announces Positive Overall Survival in Phase 3 Trial of ADCETRIS® Regimen in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)NYSE:PFEPfizer Inc
2024/03/0605 : 55Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNYSE:PFEPfizer Inc
2024/03/0600 : 00Business WirePfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare ConferenceNYSE:PFEPfizer Inc
2024/03/0523 : 03IH Market NewsFutures Pointing To Continued Weakness On Wall StreetNYSE:PFEPfizer Inc
 Showing the most relevant articles for your search:NYSE:PFE